International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease
Chengzhi Zhou, Yinyin Qin, Wei Zhao, Zhenyu Liang, Min Li, Dan Liu, Li Bai, Yahong Chen, Yan Chen, Yuan Cheng, Tianqing Chu, Qian Chu, Haiyi Deng, Yuchao Dong, Wen‐Feng Fang, Xiuhua Fu, Beili Gao, Yiping Han, Yong He, Qunying Hong, Jie Hu, Yi Hu, Liyan Jiang, Yang Jin, Fen Lan, Qiang Li, Shuben Li, Wen Li, Yaqing Li, Wenhua Liang, Gen Lin, Xinqing Lin, Ming Liu, Xiaofang Liu, Xiaoju Liu, Zhefeng Liu, Tangfeng Lv, Chuanyong Mu, Ming Ouyang, Jianwen Qin, Shengxiang Ren, Huan‐Zhong Shi, Minhua Shi, Chunxia Su, J. Su, Dejun Sun, Yongchang Sun, Huaping Tang, Huijuan Wang, Kai Wang, Ke Wang, Mengzhao Wang, Qi Wang, Wei Wang, Xiaoping Wang, Yuehong Wang, Zhijie Wang, Zirui Wang, Lin Wu, Di Wu, Baosong Xie, Min Xie, Xiaohong Xie, Zhanhong Xie, Shufeng Xu, Xiaoman Xu, Xia Yang, Yan Yin, Zongyang Yu, Jian Zhang, Jianqing Zhang, Jing Zhang, Xiaoju Zhang, Yingying Zhang, Diansheng Zhong, Qing Zhou, Xiangdong Zhou, Yanbin Zhou, Bo Zhu, Zheng-Fei Zhu, Chenxi Zou, Nanshan Zhong, Jianxing He, Chunxue Bai, Chengping Hu, Weimin Li, Yong Song, Jianying Zhou, Baohui Han, János Varga, Esther Barreiro, Hye Yun Park, Francesco Petrella, Yuichi Saito, Taichiro Goto, Hitoshi Igai, Sara Bravaccini, Michele Zanoni, Piergiorgio Solli, Satoshi Watanabe
Abstract
Background: Lung cancer combined by chronic obstructive pulmonary disease (LC-COPD) is a common comorbidity and their interaction with each other poses significant clinical challenges. However, there is a lack of well-established consensus on the diagnosis and treatment of LC-COPD. Methods: A panel of experts, comprising specialists in oncology, respiratory medicine, radiology, interventional medicine, and thoracic surgery, was convened. The panel was presented with a comprehensive review of the current evidence pertaining to LC-COPD. After thorough discussions, the panel reached a consensus on 17 recommendations with over 70% agreement in voting to enhance the management of LC-COPD and optimize the care of these patients. Results: The 17 statements focused on pathogenic mechanisms (n=2), general strategies (n=4), and clinical application in COPD (n=2) and lung cancer (n=9) were developed and modified. These statements provide guidance on early screening and treatment selection of LC-COPD, the interplay of lung cancer and COPD on treatment, and considerations during treatment. This consensus also emphasizes patient-centered and personalized treatment in the management of LC-COPD. Conclusions: The consensus highlights the need for concurrent treatment for both lung cancer and COPD in LC-COPD patients, while being mindful of the mutual influence of the two conditions on treatment and monitoring for adverse reactions.